This document has been prepared in accordance with accounting principles and practices generally accepted in Japan, and translated for reference only from the original Japanese version. The Company gives no warranty with respect to its correctness.
The original disclosure in Japanese was released on Sept. 20, 2018 at 16:00
September 20, 2018
Takara Holdings Inc.
Notice Regarding Transfer of Shares Accompanying Change in Consolidated Subsidiary
At the Board of Directors’ meeting held today, Takara Holdings Inc. (“the Company”) approved the transfer of all of its shares in its consolidated subsidiary Takara Healthcare Inc. (“Takara Healthcare”), to Shionogi Healthcare Co., Ltd. (“Shionogi Healthcare”) as of January 1, 2019 (planned).
In addition, the Company’s consolidated subsidiary Takara Bio Inc. (The First Section of Tokyo Stock Exchange, securities code number: 4974, “Takara Bio”), held a Board of Directors’ meeting today before the Company’s Board of Directors’ meeting, and resolved to transfer its functional foods business to Shionogi Healthcare through a simplified absorption-type company split, with Shionogi Healthcare as the successor company, effective January 1, 2019 (planned).
Following these actions, the Company, Takara Bio, and Shionogi Healthcare concluded an agreement on the share transfer and absorption-type company split. Details are as described below.
Shionogi Healthcare plans to implement the absorption-type merger of Takara Healthcare on January 2, 2019 (planned).
As for details, please refer to the attached file.
